EA033488B1 - Способ иммунизации против инфекции staphylococcus aureus - Google Patents

Способ иммунизации против инфекции staphylococcus aureus

Info

Publication number
EA033488B1
EA033488B1 EA201592040A EA201592040A EA033488B1 EA 033488 B1 EA033488 B1 EA 033488B1 EA 201592040 A EA201592040 A EA 201592040A EA 201592040 A EA201592040 A EA 201592040A EA 033488 B1 EA033488 B1 EA 033488B1
Authority
EA
Eurasian Patent Office
Prior art keywords
staphylococcus aureus
against staphylococcus
aureus infection
immunising against
capsular saccharide
Prior art date
Application number
EA201592040A
Other languages
English (en)
Other versions
EA201592040A1 (ru
Inventor
Ralph Leon Biemans
Dominique Boutriau
Philippe Denoel
Pierre Duvivier
Carine Goraj
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of EA201592040A1 publication Critical patent/EA201592040A1/ru
Publication of EA033488B1 publication Critical patent/EA033488B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

В изобретении раскрыт способ иммунизации против инфекции Staphylococcus aureus, включающий стадию введения пациенту-человеку однократной дозы иммуногенной композиции, содержащей капсульный сахарид Staphylococcus aureus типа 5, конъюгированный с белком-носителем с образованием конъюгата капсульного сахарида S.aureus типа 5, где конъюгат капсульного сахарида S.aureus типа 5 вводят в дозе сахарида 3-50 мкг.
EA201592040A 2013-06-05 2014-06-03 Способ иммунизации против инфекции staphylococcus aureus EA033488B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1310008.6A GB201310008D0 (en) 2013-06-05 2013-06-05 Immunogenic composition for use in therapy
PCT/EP2014/061424 WO2014195280A1 (en) 2013-06-05 2014-06-03 Immunogenic composition for use in therapy

Publications (2)

Publication Number Publication Date
EA201592040A1 EA201592040A1 (ru) 2016-06-30
EA033488B1 true EA033488B1 (ru) 2019-10-31

Family

ID=48805771

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201592040A EA033488B1 (ru) 2013-06-05 2014-06-03 Способ иммунизации против инфекции staphylococcus aureus

Country Status (24)

Country Link
US (3) US20160129101A1 (ru)
EP (1) EP3003363B1 (ru)
JP (2) JP2016524619A (ru)
KR (1) KR102266346B1 (ru)
CN (1) CN105517567A (ru)
AU (1) AU2014277027B2 (ru)
BE (1) BE1021938B1 (ru)
BR (1) BR112015029931B1 (ru)
CA (1) CA2912496C (ru)
CY (1) CY1123583T1 (ru)
DK (1) DK3003363T3 (ru)
EA (1) EA033488B1 (ru)
ES (1) ES2830785T3 (ru)
GB (1) GB201310008D0 (ru)
HR (1) HRP20201683T1 (ru)
HU (1) HUE051358T2 (ru)
IL (1) IL242584B (ru)
LT (1) LT3003363T (ru)
MX (1) MX2015016750A (ru)
PL (1) PL3003363T3 (ru)
PT (1) PT3003363T (ru)
SG (1) SG11201509406QA (ru)
SI (1) SI3003363T1 (ru)
WO (1) WO2014195280A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1896065E (pt) * 2005-06-27 2011-08-31 Glaxosmithkline Biolog Sa Processo para a preparação de vacinas
MX2012004851A (es) * 2009-10-30 2012-05-22 Novartis Ag Purificacion de sacaridos capsulares de staphylococcus aureus tipo 5 y tipo 8.
AU2015359503B2 (en) * 2014-12-10 2019-05-09 Glaxosmithkline Biologicals Sa Method of treatment
US11446371B2 (en) 2015-11-05 2022-09-20 The Texas A&M University System Targeting of ligand binding sites in ClfA
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
RU2689161C1 (ru) * 2018-10-04 2019-05-24 Федеральное бюджетное учреждение науки "Казанский научно-исследовательский институт эпидемиологии и микробиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ получения бактериальных антигенов

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007113223A2 (en) * 2006-03-30 2007-10-11 Glaxosmithkline Biologicals S.A. Immunogenic composition
WO2010151544A1 (en) * 2009-06-22 2010-12-29 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
WO2012003474A2 (en) * 2010-07-02 2012-01-05 The University Of Chicago Compositions and methods related to protein a (spa) variants

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
PL178578B1 (pl) 1993-03-23 2000-05-31 Smithkline Beecham Biolog Zawiesina cząstek 3-0-deacylowanego monofosforylolipidu A i sposób jej wytwarzania oraz kompozycja szczepionki zawierającej antygen w połączeniu z 3-0-deacylowanym monofosforylolipidem A i sposób jej wytwarzania
JP3828145B2 (ja) 1993-09-22 2006-10-04 ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 免疫原性構成物の製造のための新規シアン化試薬を使った可溶性炭水化物の活性化方法
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
UA56132C2 (ru) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиция вакцины (варианты), способ стабилизации qs21 по отношению к гидролизу (варианты), способ приготовления вакцины
US6294177B1 (en) 1996-09-11 2001-09-25 Nabi Staphylococcus aureus antigen-containing whole cell vaccine
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
JP2002523474A (ja) 1998-08-31 2002-07-30 インヒビテツクス，インコーポレイテツド ドナーの選択およびドナーの刺激によるブドウ球菌の免疫療法
ES2321892T3 (es) 1998-09-14 2009-06-12 Nabi Biopharmaceuticals Composiciones de beta-glucanos e inmunoglobulinas especificas.
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
AU9475001A (en) 2000-09-26 2002-04-08 Hybridon Inc Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
US20030113350A1 (en) 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
CA2517439C (en) 2003-03-07 2013-07-23 Wyeth Holdings Corporation Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
US7049076B2 (en) 2003-07-09 2006-05-23 Sentigen Biosciences, Inc. Method for assaying protein—protein interaction
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
JP5174457B2 (ja) 2004-05-11 2013-04-03 デ スタート デール ネーダーランデン， フェルテヘンウォールディヒィト ドール デ ミニステール ファン フォルクスヘーゾンドハイド， フェルザイン アン スポルト アジュバントとしての髄膜炎菌ｌｇｔＢＬＯＳ
EP1998802A2 (en) 2006-03-30 2008-12-10 GlaxoSmithKline Biologicals S.A. Immunogenic composition
GB0606416D0 (en) * 2006-03-30 2006-05-10 Glaxosmithkline Biolog Sa Immunogenic composition
KR20090019007A (ko) * 2006-06-12 2009-02-24 나비 바이오파마슈티컬즈 스타필로코쿠스 감염증을 치료 및 예방하기 위한 알파-독소의 용도
JP5709527B2 (ja) 2008-01-31 2015-04-30 ザ プロボスト フェローズ アンドスカラーズ オブ ザ カレッジ オブ ザ ホーリー アンド アンディバイデッドトリニティー オブ クイーン エリザベス ニア ダブリン 微生物感染症の治療
EP3461496B1 (en) 2009-06-22 2023-08-23 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
GB0913680D0 (en) * 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
ES2812523T3 (es) 2009-09-30 2021-03-17 Glaxosmithkline Biologicals Sa Conjugación de polisacáridos capsulares de Staphylococcus aureus de tipo 5 y de tipo 8
MX2012004851A (es) 2009-10-30 2012-05-22 Novartis Ag Purificacion de sacaridos capsulares de staphylococcus aureus tipo 5 y tipo 8.
ES2769425T3 (es) 2010-12-22 2020-06-25 Wyeth Llc Composiciones inmunogénicas estables de antígenos de Staphylococcus aureus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007113223A2 (en) * 2006-03-30 2007-10-11 Glaxosmithkline Biologicals S.A. Immunogenic composition
WO2010151544A1 (en) * 2009-06-22 2010-12-29 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
WO2012003474A2 (en) * 2010-07-02 2012-01-05 The University Of Chicago Compositions and methods related to protein a (spa) variants

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAUM R S, SPELLBERG B.: "Progress Toward a Staphylococcus aureus Vaccine", CLINICAL INFECTIOUS DISEASES, THE UNIVERSITY OF CHICAGO PRESS, CHICAGO, IL., US, vol. 54, no. 4, 15 February 2012 (2012-02-15), US, pages 560 - 567, XP002728207, ISSN: 1058-4838, DOI: 10.1093/cid/cir828 *

Also Published As

Publication number Publication date
GB201310008D0 (en) 2013-07-17
EP3003363B1 (en) 2020-08-19
AU2014277027B2 (en) 2017-07-20
JP6773830B2 (ja) 2020-10-21
PT3003363T (pt) 2020-11-16
CA2912496C (en) 2023-01-17
HUE051358T2 (hu) 2021-03-01
IL242584B (en) 2021-06-30
SG11201509406QA (en) 2015-12-30
US20170056490A1 (en) 2017-03-02
WO2014195280A1 (en) 2014-12-11
LT3003363T (lt) 2020-12-28
HRP20201683T1 (hr) 2020-12-25
JP2019123720A (ja) 2019-07-25
AU2014277027A1 (en) 2015-12-24
BE1021938B1 (fr) 2016-01-27
DK3003363T3 (da) 2020-11-09
KR20160018604A (ko) 2016-02-17
US20160129101A1 (en) 2016-05-12
JP2016524619A (ja) 2016-08-18
CY1123583T1 (el) 2022-03-24
US20180104322A1 (en) 2018-04-19
BR112015029931B1 (pt) 2021-01-12
EP3003363A1 (en) 2016-04-13
CN105517567A (zh) 2016-04-20
PL3003363T3 (pl) 2021-04-06
KR102266346B1 (ko) 2021-06-17
SI3003363T1 (sl) 2020-12-31
CA2912496A1 (en) 2014-12-11
MX2015016750A (es) 2016-04-13
ES2830785T3 (es) 2021-06-04
EA201592040A1 (ru) 2016-06-30

Similar Documents

Publication Publication Date Title
GB201101665D0 (en) Immunogenic compositions
EA033488B1 (ru) Способ иммунизации против инфекции staphylococcus aureus
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
NZ720736A (en) Antibody drug conjugates (adcs) with kinesin spindel protein (ksp)
MX2017012393A (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
JP2013155188A5 (ru)
AR108021A1 (es) Conjugados de anticuerpo-principio activo (adcs) de inhibidores de ksp con anticuerpos anti-b7h3
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
EA201591701A1 (ru) Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv
MX344476B (es) Metodos de tratar trastornos pulmonares con formulaciones de amikacina liposomal.
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
RU2018125622A (ru) Способ применения карримицина против резистетности инфекции, спровоцированной микобактерией туберкулеза
CR20140005A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
BR112015023481A2 (pt) composição de lipossoma de liberação controlada de fármaco
WO2015048503A3 (en) N-arylmethyl sulfonamide negative modulators of nr2a
WO2016137806A3 (en) Doses and methods of administering telavancin
MX2017016858A (es) Composiciones inmunogenicas.
MX2015013401A (es) Procedimiento de tratamiento.
EA201590350A1 (ru) Комбинации с пептидом с циклизованной основной цепью
MX2017007652A (es) Metodo de tratamiento.
MX349930B (es) Composiciones inmunogenas.
CO2018001531A2 (es) Lisobactina para su uso en el tratamiento de la mastitis bovina
NZ740627A (en) Oral suspension for treating eosinophilic esophagitis
UA69674U (ru) Способ лечения больных на эритематозно-бульозной рожей
MY159675A (en) Clerodane derivatives for modulation of leukotriene receptor activity and related diseases

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM